Loading
No description yet: the sentence for this tag has not been written. 3 records carry it: 3 technologies.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
After ruxolitinib: belumosudil, axatilimab and ibrutinib in chronic GvHD Three more drugs are licensed for chronic GvHD that has not responded to earlier treatment. Their response rates look high, between half and three quarters, but they come from trials with no comparison group. Ibrutinib is the cautionary case: it looked good in a single-arm study and then did not beat prednisone alone when tested against placebo. | none | rejuvenation, survivorship, transplant | |||
Extracorporeal photopheresis for graft-versus-host disease Blood is taken out through a machine, the white cells are treated with a light-sensitive drug and ultraviolet light, and given back. It is used for GvHD that steroids have not controlled, mainly skin and mouth, and it spares people more immunosuppression. Improvement builds over months, so it means two sessions a week for a long time. | none | rejuvenation, survivorship, transplant | |||
When steroids fail: ruxolitinib for steroid-refractory GvHD First treatment for graft-versus-host disease is steroids, and in about half of people with chronic disease they do not work or cannot be reduced. Ruxolitinib is the only drug that has beaten the alternatives in a randomised trial here, and it has done so twice. About half of people respond; the common problems are low platelets and low haemoglobin. | none | rejuvenation, survivorship, transplant |